Equillium, Inc.

"At Equillium, our community matters!" Thank you Life Science Cares San Diego and Feeding San Diego for your partnership! #LifeScienceCaresSanDiego #FeedingSanDiego #CommunityDay #SocialResponsibility #FunWellnessDay

As we enter the weekend, we want to welcome our newest team member, Hareth Yousef. Hareth joins the Clinical Operations Team as a Clinical Trial Associate. He will be supporting the EQUATOR program and the EQ101 program in alopecia areata. 

Today we announced positive topline data from our Phase 2, single dose, proof-of-concept (PoC) study of EQ101 in adult patients with moderate, severe or very-severe alopecia areata, an autoimmune disease driven by an immune cell attack of the hair follicles that causes hair loss. Results from the study demonstrated a favorable safety and tolerability profile with no serious adverse events and improvements in SALT scores above historically low placebo response rates. Of all subjects (baseline SALT of 35 - 100) that completed 24 weeks of treatment, 20% achieved a SALT score of less than 20 by week 24. Of those subjects with moderate to severe alopecia areata (SALT score 35 - 95) at baseline that completed 24 weeks of treatment, 29% achieved a SALT score of less than 20 by week 24, and a mean SALT improvement from baseline of 18%.    Equillium Announces Positive Topline Data from Phase 2 Study of EQ101 in Alopecia Areata ·    20% of all subjects that completed 24-week treatment period achieved SALT ≤ 20 ·    29% of completed subjects with moderate to severe disease (baseline SALT 35 to <95) achieved SALT ≤ 20 ·    EQ101 was well tolerated in subjects with alopecia areata with no serious adverse events reported ·    Data supports advancing EQ101 development in alopecia areata to include dose and delivery optimization ·    Data provides further support for opportunistic expansion in other dermatological conditions where IL-2, IL-9 and IL-15 inhibition is important such as vitiligo and atopic dermatitis https://lnkd.in/gqVvyqNb

In recognition of International Celiac Disease Awareness Day, Celiac Disease Foundation supports schools and students nationwide for their annual Celiac Strong Day. See how you can contribute here: https://lnkd.in/gzbHTQVk

Equillium Announces Poster Presentation at the Annual Meeting of The American Association of Immunologists Poster, titled “Surface CD6 regulates T cell adhesion and migration through direct ligand interaction and stabilization of VLA4” highlights that: -         CD6 contributes to cell adhesion/migration both through direct ligand interactions with activated leukocyte cell adhesion molecule (ALCAM) and through the stabilization of cell membrane VLA4 -         Blockade of CD6 through itolizumab prevents the trans-endothelial migration of effector T cells -         Data supports the differentiated mechanism of action of itolizumab “Our data demonstrates that CD6 contributes to cell adhesion/migration both through direct ligand interactions with ALCAM and through the stabilization of cell membrane VLA4, and that these functions can be abrogated by itolizumab,” said Dr. Stephen Connelly, chief scientific officer at Equillium. “We previously showed that blockade of CD6 prevents the trans-endothelial migration of effector T cells and this new data further elucidates the molecular mechanism. Moreover, our data continues to demonstrate that increased levels of CD6 facilitate the migration of pathogenic effector T cells into inflamed tissues and that itolizumab can modulate not only their activity, but trafficking too.” Full poster available here: https://bit.ly/3UoItTq

Great interview with Equillium CEO, Bruce Steel, in recent Biotech & Pharmaceuticals report by The Wall Street Transcript https://bit.ly/4b5AS2O

Drug Update: In Phase 1B study, itolizumab, for the treatment of lupus nephritis improved a biomarker for kidney function and continues to show promise. Read the announcement:

Equillium welcomes Courtney Burke, Senior Clinical Trial Manager, supporting our Phase 3 EQUATOR study in aGVHD. Courtney has worked in Clinical Development for over 10 years, including experiences at Quintiles, Acadia, Tocagen, Arcus, OBI Pharma and Triumvira and has earned a Bachelor of Health Science and a Master of Sciences. In her spare time, she is an avid ATV enthusiast, a lover of French Bulldogs and a volunteer with AYSO. Great to have you on board Courtney!

#foodbank

RAPID ARCHIVE for the educational event we sponosred is now online. Learn more about how to treat GVHD today . . . and tomorrow here: https://bit.ly/3RKpjWN #gvhd